Intriguingly, CDK4, the binding partner of CDK6, showed no obvious alterations in lenvatinib-resistant cells, which revealed the distinct role of the noncanonical role of CDK6 in the regulation of lenvatinib resistance in HCC cells. The gene discussed is CDK4; the disease is hepatocellular carcinoma.